Harnessing the power of traceable system C-GAP: homologous-targeting to fire up T-cell immune responses with low-dose irradiation
Weijie Zhuang,
Kuangwu Pan,
Jie Wu
и другие.
Journal of Nanobiotechnology,
Год журнала:
2025,
Номер
23(1)
Опубликована: Март 12, 2025
While
radiotherapy-induced
immunogenic
cell
death
(ICD)
holds
potential
for
enhancing
cancer
immunotherapy,
the
conventional
high-dose
irradiation
often
leads
to
an
immunosuppressive
microenvironment
and
systemic
toxicity.
Therefore,
a
biomimetic
nanoplatform
membrane
coated-nitrogen-doped
graphene
quantum
dots
combined
with
Au
nanoparticles
(C-GAP)
was
developed
in
this
study.
Firstly,
homologous
traceable
targeting
features
of
C-GAP
enables
tumor-selective
accumulation,
providing
reference
selection
timing
radiotherapy.
Secondly,
radiosensitization
by
Low-dose
(LDI)
amplifies
reactive
oxygen
species
(ROS)
generation
trigger
potent
ICD.
Thirdly,
remarkable
immune
remodeling
induced
enhances
CD8+
T
infiltration
effector
function.
Single-cell
RNA
sequencing
revealed
that
C-GAP-LDI
combination
upregulates
TNF
CCL
signaling
pathway
expression
tumor-infiltrating
cells
which
potentiates
tumor
eradication.
Our
findings
present
novel
approach
safe
effective
radioimmunotherapy,
where
sensitized
LDI
achieves
therapeutic
enhancement
through
precise
ICD
induction
activation.
Язык: Английский
Catalase-Knockout Complements the Radio-Sensitization Effect of Titanium Peroxide Nanoparticles on Pancreatic Cancer Cells
Molecules,
Год журнала:
2025,
Номер
30(3), С. 629 - 629
Опубликована: Янв. 31, 2025
In
previous
studies,
titanium
peroxide
nanoparticles
(PAA-TiOx
NPs)
with
surfaces
functionalized
using
polyacrylic
acid
(PAA)
and
hydrogen
(H2O2)
demonstrated
a
synergistic
effect
when
combined
X-ray
irradiation.
The
combination
generated
H2O2
reactive
oxygen
species
(ROS)
that
enhanced
the
irradiation
efficacy.
present
study,
we
examined
relationship
between
catalase
PAA-TiOx
NPs
sensitization
to
radiation
because
is
primary
antioxidant
enzyme
converts
water
oxygen.
Catalase-knockout
PANC-1
(dCAT)
cells
were
CRISPR/Cas9
system,
which
was
confirmed
by
suppression
of
expression
in
mRNA
protein
levels
resulted
an
81.7%
decrease
activity
compared
wild-type
cells.
Catalase
deficiency
found
increase
production
ROS,
particularly
hypoxia.
Also,
5
Gy
7-fold
survival
fraction
(SF;
p
<
0.01)
dCAT
rates
documented
Interestingly,
treatment
3
SF
similar
observed
treated
same
but
at
higher
dose
(5
Gy).
These
results
suggest
strategy
inhibition
could
be
used
establish
advanced
for
pancreatic
cancer
Язык: Английский
An aggregation-induced emission-active lysosome hijacker: sabotaging lysosomes to boost photodynamic therapy efficacy and conquer tumor therapeutic resistance
Materials Today Bio,
Год журнала:
2025,
Номер
31, С. 101564 - 101564
Опубликована: Фев. 8, 2025
Therapeutic
resistance
is
a
major
challenge
in
clinical
cancer
theranostics,
often
leading
to
treatment
failure
and
increased
patient
mortality.
Breaking
this
therapeutic
deadlock,
enhancing
the
efficacy
of
treatments,
ultimately
improving
survival
rates
are
both
highly
desirable
significantly
challenging
goals.
Herein,
we
have
developed
new
fluorescent
luminogen,
QM-DMAC,
which
features
aggregation-induced
emission
(AIE),
exceptional
viscosity-responsive
properties.
The
AIE-active
QM-DMAC
can
specifically
stain
lysosomes
tumor
cells,
offering
high
signal-to-noise
ratio
enabling
specific
visualization
variations
lysosomal
viscosity,
such
as
those
induced
by
inflammation
or
autophagy.
Furthermore,
effectively
generates
reactive
oxygen
species
(ROS)
under
white
light
irradiation,
precisely
induces
ROS-mediated
membrane
permeabilization
(LMP)
lysosome
rupture.
This
causes
severe
cell
damage
restores
sensitivity
cells
radiotherapy
chemotherapy.
Thus,
serves
efficient
lysosome-targeting
photosensitizer
an
excellent
sensitizer.
innovative
"lysosome
hijacking"
strategy
maximizes
photodynamic
therapy,
conquering
boosting
synergistic
effect
when
integrated
with
conventional
It
provides
novel
approach
design
theranostic
agents
for
theranostics.
Язык: Английский
Novel Intravenous Formulation for Radiosensitization in Osteosarcoma Treatment
Materials Today Bio,
Год журнала:
2025,
Номер
32, С. 101682 - 101682
Опубликована: Март 18, 2025
Язык: Английский
Radiosensitization Strategies for Hepatocellular Carcinoma: Mechanisms, Therapeutic Advances, and Clinical Perspectives
Critical Reviews in Oncology/Hematology,
Год журнала:
2025,
Номер
unknown, С. 104773 - 104773
Опубликована: Май 1, 2025
Язык: Английский
Golden insights for exploring cancer: delivery, from genes to the human body using bimetallic Au/Ag nanostructures
Discover Oncology,
Год журнала:
2025,
Номер
16(1)
Опубликована: Май 25, 2025
Sweeping
contact
with
cancer
continues
to
rise
globally,
which
has
led
advanced
research
on
new
treatment
approaches;
nanotechnology
become
crucial
targeted
therapy.
Within
the
intimate
of
nanomaterials,
Au/Ag
nanostructures
have
emerged
as
highly
attractive
because
their
distinctive
desirable
characteristics
and
prospective
roles
in
diagnosis
well
The
developed
revealed
remarkable
biocompatibility,
optically
recursive
alteration,
magnificently
improved
therapeutic
effects
gold
silver
conjunction
each
other.
This
review
addresses
molecular
systemic
aspects
research,
including
impact
genetic
pathways
use
administration
human
organism.
We
explain
some
related
mechanisms
action,
such
photothermal
therapy
(PTT),
photodynamic
(PDT),
drug
delivery
systems
where
they
display
potential
benefits
towards
offering
a
more
approach
fewer
side
effects.
latest
development
shown
that
prospect
real-time
imaging
biomarker
identification,
owing
this
are
being
viewed
tool
for
individualized
treatment.
However,
there
still
limitations:
challenges
scaling
up,
biological
safety,
bringing
it
clinic.
It
is
therefore
incumbent
upon
these
managements
overcome
hurdles
optimize
impact.
As
result,
current
findings
briefly
reviewed,
directions
discussed
support
revolutionary
role
Язык: Английский
Radiobiological perspective on metrics for quantifying dose enhancement effects of High-Z nanoparticles
Frontiers in Nanotechnology,
Год журнала:
2025,
Номер
7
Опубликована: Июнь 3, 2025
High
atomic
number
(high-Z)
metal
nanoparticles
(NPs)
have
emerged
as
transformative
radiosensitizers
in
cancer
radiotherapy,
offering
the
potential
to
amplify
tumor-specific
radiation
effects
while
sparing
healthy
tissues.
However,
clinical
translation
of
these
NPs
is
hindered
by
inconsistent
methodologies
for
quantifying
dose
enhancement
and
a
limited
understanding
how
biological
complexity
influences
therapeutic
outcomes.
This
review
systematically
evaluates
current
metrics
assessing
high-Z
NP-mediated
radiosensitization,
including
physical
factors
(DEF),
sensitizer
ratios
(SER),
survival
fraction
(SF),
DNA
damage
biomarkers.
We
critically
analyze
interplay
between
NP
properties,
parameters,
tumor
microenvironment
(TME)
dynamics,
emphasizing
hypoxia,
immune
suppression,
stromal
barriers
modulate
efficacy.
A
key
innovation
proposal
multidimensional
Radiosensitization
Index
(RSI),
integrating
deposition,
reactive
oxygen
species
(ROS)
kinetics,
repair
inhibition,
reprogramming,
endpoints.
further
highlight
translational
challenges
such
toxicity,
batch-to-batch
variability,
discordance
vitro
vivo
models,
underscoring
need
standardized
protocols
advanced
3D/organoid
platforms.
By
bridging
radiobiology,
nanotechnology,
practice,
this
work
provides
roadmap
optimizing
NP-enhanced
radiotherapy
accelerating
its
integration
into
precision
oncology.
Язык: Английский
HPV status and immunohistochemical analysis of p16, p53 and PD‑L1 expression as prognostic biomarkers in patients with squamous cell anal cancer receiving definitive radiotherapy/chemoradiotherapy
Oncology Letters,
Год журнала:
2024,
Номер
28(2)
Опубликована: Июнь 25, 2024
Anal
squamous
cell
carcinoma
(SCC)
treated
with
definitive
radiotherapy
(RT)/chemoradiotherapy
(CRT)
has
shown
high
success
rates,
yet
challenges
such
as
treatment
resistance
and
recurrence
persist.
The
present
study
aimed
to
investigate
the
associations
between
immunohistochemical
(IHC)
evaluation,
response
prognosis
in
anal
SCC.
A
retrospective
cohort
analysis
included
42
patients
SCC
at
a
single
institution
2006
2022.
Human
papillomavirus
(HPV)
status
was
determined,
IHC
of
p16,
p53
PD‑L1
expression
conducted
using
formalin‑fixed,
paraffin‑embedded
biopsies.
complete
RT/CRT
observed
71.4%
patients.
Recurrence
occurred
38.1%
cases,
which
7.1%
had
local‑regional
(LRR),
14.3%
distant
(DR),
16.7%
both
LRR
DR.
HPV
positivity
(71.4%)
significantly
associated
p16
positivity.
Lack
HPV‑negative
status,
p16‑negative
increased
In
addition,
p53‑positive
LRR.
positivity,
defined
combined
positive
score
(CPS)
≥1%
found
73.8%
patients,
exhibited
significant
CPS
≥
1%
also
an
Univariate
revealed
that
age
<65
years,
were
5‑year
overall
survival
(OS),
while
response,
p53‑negative
disease‑free
(DFS).
Multivariate
identified
years
are
independent
prognostic
factors
for
OS,
DFS.
conclusion,
these
findings
suggust
identification
poor
biomarkers
diagnosis
may
be
used
guide
personalized
strategies,
combination
immunotherapy
standard
CRT
potentially
providing
improved
outcomes.
Язык: Английский
Nanoparticle-Enabled In Situ Drug Potency Activation for Enhanced Tumor-Specific Therapy
European Journal of Pharmaceutical Sciences,
Год журнала:
2024,
Номер
205, С. 106989 - 106989
Опубликована: Дек. 14, 2024
Язык: Английский
Metabolizable alloy clusters assemble nanoinhibitor for enhanced radiotherapy of tumor by hypoxia alleviation and intracellular PD-L1 restraint
Journal of Nanobiotechnology,
Год журнала:
2024,
Номер
22(1)
Опубликована: Дек. 19, 2024
Cancer
radiotherapy
(RT)
still
has
limited
clinical
success
because
of
the
obstacles
including
radioresistance
hypoxic
tumors,
high-dose
X-ray–induced
damage
to
adjacent
healthy
tissue,
and
DNA-damage
repair
by
intracellular
PD-L1
in
tumor.
Therefore,
overcome
these
multifunctional
core–shell
BMS@Pt2Au4
nanoparticles
(NPs)
are
prepared
using
nanoprecipitation
followed
electrostatic
assembly.
Pt2Au4
clusters
released
from
NPs
alleviate
tumor
hypoxia
catalyzing
decomposition
endogenous
H2O2
generate
O2
as
well
enhancing
X-ray
deposition
at
site,
which
thereby
reduce
required
dose.
The
BMS-202
molecules
simultaneously
blockade
on
cells,
causing
activation
effector
T
cells
inhibition
repair.
Consequently,
based
enhance
expression
calreticulin
cancer
transposition
HMGB1
nucleus
cytoplasm,
generation
reactive
oxygen
species
(ROS),
DNA
breakage
apoptosis
vitro.
rate
reached
92.5%
under
three
cycles
1-Gy
irradiation
vivo.
In
conclusion,
therapeutic
outcome
supports
high-efficiency
tumors
expressing
PD-L1.
Язык: Английский